Isotechnika Selected for Oral Presentation at the American Transplant Congress

Edmonton, Canada (ots/PRNewswire) -

- Trades on Toronto Stock Exchange - (TSX:ISA)

Isotechnika today announced that the Company has been selected to
give an oral presentation during the American Transplant Congress in
San Francisco, California.

An overview of the latest Phase 2b kidney transplant trial
(PROMISE) results will be presented during an oral presentation by
Dr. Stephen Busque, one of the principal investigators involved in
the PROMISE trial. Dr. Busque's oral presentation is scheduled to
take place on Sunday, May 6 at 5:20 p.m. Interested parties will be
able to access Dr. Busque's presentation (PDF file format only) by
visiting the Company's corporate web site at www.isotechnika.com on
Monday, May 7th.

"This oral presentation allow us the opportunity to highlight the
latest Phase 2b results to transplant surgeons, physicians, and other
health care professionals," stated Dr. Randall Yatscoff,
Isotechnika's President & CEO. "The data presented at the American
Transplant Congress will demonstrate the favourable safety and
efficacy profile of ISA247 in kidney transplantation."

In addition to the oral presentation, Isotechnika will host an
evening educational symposium titled "Unleashing the Power of CNi's"
on Saturday, May 5th at 7:30 p.m. at the San Francisco Marriott
Hotel. The symposium will highlight the use of ISA247 for the
prevention of organ transplant rejection. The evening will focus on
the use of calcineurin inhibitors, the design of ISA247, and the
potential for this design to result in improvements in both safety
and efficacy for transplant and psoriasis patients. Results from the
PROMISE trial will also be presented. The symposium will also provide
attendees the opportunity to meet clinical trial investigators
currently involved in the Company's PROMISE trial.

To register or learn more about the symposium please visit
www.isotechnika.com/symposium. The formal presentations from the
evening symposium will be recorded and available to all interested
parties by visiting the Company's corporate web site
(www.isotechnika.com) starting Monday, May 7th.

North American Phase 2b Kidney Transplant Trial Design

Forty-one centers across North America have been contracted to
perform the trial, including thirty-seven centers in the United
States and four centers in Canada. The primary endpoint of the trial
is defined as non-inferiority in biopsy proven acute rejection (BPAR)
episodes in patients receiving ISA247 for six months as compared to
the tacrolimus control which is currently the North American leading
transplant drug in this class. Additionally, kidney function and
other laboratory parameters will be monitored for the duration of the
trial. The overall goal of the trial is to find the most appropriate
dose that will result in efficacy (lack of acute rejection) with
minimal side effects that are typically seen with other calcineurin
inhibitors such as cyclosporine and tacrolimus.

A total of 332 de novo (newly transplanted) kidney transplant
patients will be enrolled in this trial. Patients will be placed into
one of four separate treatment groups; three different dose groups of
ISA247 (0.4 mg/kg, 0.6 mg/kg, and 0.8 mg/kg twice daily) compared
with the fourth group, a tacrolimus (0.05 mg/kg twice daily) control
arm. Patients in all four treatment groups will have their doses
adjusted in order to achieve pre-defined blood levels of either
ISA247 or tacrolimus. All patients will receive oral treatment of
drug (ISA247 or tacrolimus) over a six month period along with other
standard immunosuppressive therapies used following transplantation.
Patients completing the six month trial will be given the option to
continue therapy for an additional six months. The objective is to
gather long term safety and efficacy data in de novo transplant
patients.

About Isotechnika

Edmonton-based Isotechnika Inc. is an international
biopharmaceutical company focused on the discovery and development of
novel immunosuppressive therapeutics that are safer than currently
available treatments. Isotechnika looks to become the leader in
development of immunosuppressant therapies. Isotechnika's lead drug,
ISA247, has successfully completed a Phase 3 Canadian trial for the
treatment of moderate to severe psoriasis. ISA247 is Currently being
investigated in a combined Phase 3 European/Canadian psoriasis trial
and a Phase 2b North American trial for the prevention of kidney
graft rejection. One of our partners, Lux Biosciences, has received
permission from the regulatory bodies in the United States, Canada,
Austria, Germany, France and the United Kingdom to investigate ISA247
in three separate pivotal Phase 2/Phase 3 trials for the treatment of
non-infectious uveitis and as a maintenance therapy in uveitis.

Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA". More information on Isotechnika can
be found at www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and commercialize voclosporine for all transplant
indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use of voclosporine and TAFA93 specifically with drug eluting devices
for the non-systemic treatment of vascular, cardiovascular, target
vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive license to develop and commercialize conjugates consisting
of Cellgate's patented transporter technology for the topical
delivery of voclosporine in patients suffering from mild to moderate
psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug, voclosporine for the treatment and prophylaxis of all
ophthalmic diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Dr. Randall Yatscoff, President & COO,
Isotechnika Inc., Phone: +1-(780)-487-1600 Ext. 246, Fax:
+1-(780)-484-4105, Email: ryatscoff@isotechnika.com; Stephanie
Gillis-Paulgaard, Director, Corporate Communications, Isotechnika
Inc., Phone: +1-(780)-909-4661, Fax: +1-(780)-484-4105,
E-mail:sgillis-paulgaard@isotechnika.com